#### (19) World Intellectual Property Organization International Bureau





#### (43) International Publication Date 18 October 2001 (18.10.2001)

### (10) International Publication Number WO 01/76601 A3

(51) International Patent Classification7: A61K 31/46, 31/137 // (A61K 31/46, 31:137)

(21) International Application Number: PCT/EP01/03889

5 April 2001 (05.04.2001) (22) International Filing Date:

(25) Filing Language: English

English (26) Publication Language:

(30) Priority Data: 0008485.5 7 April 2000 (07.04.2000)

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JENKINS, Richard, John [GB/US]; SmithKline Beecham Corporation, Five Moore Drive, Research Triangle Park, NC 27709 (US). RICHARDS, David, Hugh [GB/GB]; GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT (GB).


- Agent: LEAROYD, Stephanie, Anne; Glaxo Smith Kline, Corprate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH. GM. KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

with international search report

(88) Date of publication of the international search report: 21 February 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(57) Abstract: The present invention is concerned with pharmaceutical formulations comprising a combination of salmeterol and ipratropium and the use of such formulations in medicine, particularly in the prophylaxis and treatment of respiratory diseases.

#### INTERNATIONAL SEARCH REPORT

Intern in an Application No PCT/EP 01/03889

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/46 A61K31/137 //(A61K31/46,31:137)

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE

Category °	Citation of document, with indication, where appropriate, or	Relevant to claim No.			
х	MATERA M G ET AL: "A COMBINA CLINICAL RECOMMENDED DOSAGES AND IPRATROPIUM IS NOT MORE E SALMETEROL ALONE IN PATIENTSWOBSTRUCTIVE PULMONARY DISEASE RESPIRATORY MEDICINE, BAILLIE LONDON, GB, vol. 90, no. 8, 1996, pages 4 XP001021998 ISSN: 0954-6111 the whole document	1-13			
X	WO 99 65464 A (BOEHRINGER ING PHARMA) 23 December 1999 (199 page 4, line 7-20; claims 1-2	99-12-23)	1-13		
X Fu	rther documents are listed in the continuation of box C.	Patent family members are listed	in annex.		
'A' document cons 'E' earlier filing 'L' document which citati 'O' document othe	categories of cited documents:  nent defining the general state of the art which is not idered to be of particular relevance or document but published on or after the international date of the control of the cited to establish the publication date of another ion or other special reason (as specified) or ment referring to an oral disclosure, use, exhibition or or means of the cited of the cited to establish the publication date of another ion or other special reason (as specified) or or or means or oral disclosure, use, exhibition or or or means or or or the international filing date but than the priority date claimed	or priority date and not in conflict with cited to understand the principle or the invention  "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the divided to involve an inventive step when the divided to involve an involve and its combined with one or ments, such combination being obvious in the art.	<ul> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled</li> </ul>		
Date of th	e actual completion of the international search	Date of mailing of the international se	earch report		
	25 October 2001	06/11/2001	06/11/2001		
Name and	d mailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer Herrera, S			

2

## INTERNATIONAL SEARCH REPORT

Interr Conal Application No
PCT/EP 01/03889

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	101/21 01/03003	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
P,X	NOORD VAN J A ET AL: "LONG-TERM TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH SALMETEROL AND THE ADDITIVE EFFECT OF IPRATROPIUM" EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 15, no. 5, May 2000 (2000-05), pages 878-885, XP001021107 ISSN: 0903-1936 abstract	1-13	

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 11--13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr Onal Application No
PCT/EP 01/03889

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9965464	Α	23-12-1999	DE DE	19827178 A1 19842963 A1	27-04-2000 23-03-2000
			ΑU	4552199 A	05-01-2000
			BR	9911351 A	13-03-2001
			CN	1307470 T	08-08-2001
			EP	1087750 A1	04-04-2001
			NO	20006318 A	30-01-2001
			WO	9965464 A1	23-12-1999